Hostname: page-component-7479d7b7d-jwnkl Total loading time: 0 Render date: 2024-07-12T01:07:36.814Z Has data issue: false hasContentIssue false
  • English
  • Français

delta-Opioid Modulation of Striatal Dopaminergic Activity in Mice

Published online by Cambridge University Press:  18 September 2015

Ashok K. Dua  and
Carl Pinsky
Ashok K. Dua*
Affiliation:
Department of Pharmacology and Therapeutics, University of Manitoba
Carl Pinsky*
Affiliation:
Department of Pharmacology and Therapeutics, University of Manitoba
*
Department of Pharmacology and Therapeutics, University of Manitoba, Faculty of Medicine, 770 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0W3
Department of Pharmacology and Therapeutics, University of Manitoba, Faculty of Medicine, 770 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0W3
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Mu- and delta-opioid subtype receptor antagonists were tested in the mouse for their effects on vertical climbing activity, an index of striatal dopaminergic activity. The selective delta-opioid antagonist ICI 154 129 (1/1) by itself enhanced vertical climbing activity in a dose-related manner, whereas the mu-opioid antagonist naloxone by itself was inactive on climbing behavior. Naloxone increased the climbing-stimulant effect of I/I. Unstimulated vertical climbing activity was reduced, and all opioid-antagonist enhancement of climbing behavior was antagonized, by the competitive dopamine antagonist haloperidol in dose-related fashion. The observed motor-enhancement effect of a selective delta-opioid receptor antagonist is the first demonstration of physiologically-significant tonic activity on a central opioid receptor. Our observations suggest that 1/1 may be useful clinically in striatal dopamine-deficient disease conditions such as parkinsonism.

Type
Articles
Information
Canadian Journal of Neurological Sciences , Volume 12 , Issue 1 , February 1985 , pp. 60 - 64
Copyright
Copyright © Canadian Neurological Sciences Federation 1985

References

Atweh, SF, Kuhar, MJ (1983) Distribution and physiological significance of opioid receptors in the brain Br. Med. Bull. 39: 47–52.CrossRefGoogle Scholar
Biggio, G, Casu, M, Corda, MG, Dibello, C, Glessa, GL (1978) Stimulation of dopamine synthesis in caudate nucleus by intrastriatal enkephalins and antagonism by naloxone. Science 200: 552–554.CrossRefGoogle ScholarPubMed
Bowen, WD, Gentleman, S, Herkenham, M, Pert, CB (1981) Interconverting mu and delta forms of the opiate receptor in rat striatal patches. Proc. Natl. Acad. Sci. 78: 4818–4822.CrossRefGoogle ScholarPubMed
Bulmer, MG (1965) Principles of statistics. Oliver and Boyd (publ.), Edinburgh. 183–203.Google Scholar
Calne, DB (1977) Developments in the pharmacology and therapeutics of parkinsonism. Ann. Neurol. 1: 111–119.CrossRefGoogle ScholarPubMed
Calne, DB (1978) Parkinsonism: clinical and neuropharmacologic aspects. Postgrad. Med. 64: 82–88.CrossRefGoogle ScholarPubMed
Calne, DB (1983) Current views on Parkinson’s Disease. Can. J. Neurol. Sci. 10: 11–15.CrossRefGoogle ScholarPubMed
Constentin, J, Protais, P, Schwartz, JC (1975) Rapid and dissociated changes in sensitivities of different dopamine receptors in the mouse brain. Nature 257: 405–407.CrossRefGoogle Scholar
Cotzias, GC, Papavasiliou, PS, Tolosa, ES, Mendez, JS, Bell-Midura, M (1976) Treatment of parkinsonism with apomorphines: possible role of growth hormone. N. Engl. J. Med. 294: 567–572.CrossRefGoogle ScholarPubMed
Cowan, A, Gemerek, DE (1982) In vivo studies with ICI 154 129, a putative delta receptor antagonist. Life Sci. 31: 2213–2216.CrossRefGoogle Scholar
Dascombe, MJ, Foote, GG (1981) Intrastriatal injection of apomorphine and climbing behavior in chronically cannulated mice. Br. J. Pharmac. 73: 236P.Google Scholar
Dua, AK, Pinsky, C (1984) delta-Opiate receptor blockade promotes striatal dopamine-specific climbing activity in mice and suggests a novel antiparkinsonism therapy. Federation Proc. 43: 654.Google Scholar
Ehringer, H, Hornykiewicz, O (1960) Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38: 1236–1239.CrossRefGoogle Scholar
Fields, HL, Emson, PC, Leigh, BK, Gilbert, RFT, Iversen, LL (1980) Multiple opiate receptor site on primary afferent fibres. Nature 284: 351–353.CrossRefGoogle Scholar
Goldstein, M, Lieberman, A, Battista, AF, Lew, JY, Matsumoto, Y (1978) Experimental and clinical studies on bromocriptine in the parkinsonian syndrome. Acta Endocrinol. (Kbh.) 88: Suppl. 216, 57–66.Google Scholar
Goodman, RR, Snyder, SH, Kuhar, MJ, Young, WS (1980) Differentiation of delta and mu opiate receptor localization by light microscopic autoradiography Proc. Natl. Acad. Sci. U.S.A. 77: 6239–6253.CrossRefGoogle Scholar
Gormley, JJ, Morley, JS, Priestley, T, Shaw, JS, Turnbull, MJ, Wheeler, H (1982) In vivo evaluation of the opiate delta receptor antagonist ICI 154, 129. Life Sci. 31: 1263–1266.Google Scholar
Granerus, AK (1978) Factors influencing the occurence of “on-off” symptoms during long-term treatment with L-dopa. Acta. Med. Scand. 203:75–81.CrossRefGoogle Scholar
Havemann, U, Turski, L, Kuschinsky, K (1982) Role of opioid receptors in the substantia nigra in morphine-induced muscular rigidity. Life Sci. 31: 2319–2322.CrossRefGoogle ScholarPubMed
Hornykiewicz, O (1973a) Dopamine in the basal ganglia. Br. Med. Bull. 29: 172–178.CrossRefGoogle ScholarPubMed
Hornykiewicz, O (1973b) Parkinson’s disease from brain homogenate to treatment. Federation Proc. 32: 183–190.Google ScholarPubMed
Iwatsubo, K (1982) Narcotic analgesics and nirostriatal dopaminergic neurons. TIPS, 3: 64–66.Google Scholar
Lieberman, A, Kupersmith, M, Gopinathan, G, Estey, E, Goodgold, A, Goldstein, M (1976) Treatment of Parkinson’s disease with bromocriptine. N. Engl. J. Med. 295: 1400–1404.CrossRefGoogle ScholarPubMed
Marcais, H, Protais, P, Costentin, J (1979) Hypersensitivity of the climbing behavior response to apomorphine induced by a short depression of dopaminergic neuron activity. Neuropharmacol. 18: 845–849.CrossRefGoogle Scholar
Marien, M, Jhamandas, K (1983) Release of endogenous dopamine (DA) from rat striatum in vitro: effects of L-glutamic acid (l-glu) and a delta opioid agonist. Soc. for Neurosci. Abst. 9: 587.Google Scholar
Marien, M, Brien, J, Jhamandas, K (1983) Regional release of [3H]dopamine from rat brain in vitro: effects of opioids on release induced by potassium, nicotine, and L-glutamic acid. Can. J. Physiol. Pharmacol. 61:43–60.CrossRefGoogle ScholarPubMed
Marsden, CD, Parkes, JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s Disease. The Lancet 1: 345–349.CrossRefGoogle ScholarPubMed
Ninkovic, M, Hunt, SP, Emson, PC, Iversen, LL (1981) The distribution of multiple opiate receptors in bovine brain. Brain Res. 214:163–167.CrossRefGoogle ScholarPubMed
Nutt, JG, Rosin, AJ, Eisler, T, Calne, DB, Chase, TN (1978) Effects of an opiate antagonist on the movement disorders. Arch. Neurol. 35: 810–811.CrossRefGoogle ScholarPubMed
Pollard, H, Llorens, C, Schwartz, JC, Gros, C, Dray, F (1978) Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigro-striatal dopaminergic system: Lesion studies. Brain Res. 151:392–393.CrossRefGoogle Scholar
Protais, P, Costentin, J, Schwartz, JC (1976) Climbing behavior induced by apomorphine in mice. A simple test for the study of dopamine receptors in striatum. Psychopharmacol. 50: 1–6.CrossRefGoogle Scholar
Protais, P, Bonnet, J-J, Constentin, J, Schwartz, JC (1984) Rat climbing behavior elicited by stimulation of cerebral dopamine receptors. Naunyn-Schm. Arch. Pharmacol. 325: 93–101.CrossRefGoogle ScholarPubMed
Reisine, TD, Rossor, M, Spokes, E, Iversen, LL, Yamamura, HI (1979) Alterations in brain opiate receptors in Parkinson’s disease. Brain Res. 173: 378–382.CrossRefGoogle ScholarPubMed
Seeman, P (1980) Brain dopamine receptors. Pharmacol. Rev. 32:229–313.Google ScholarPubMed
Shaw, J S, Miller, L, Turnbull, MJ, Gormley, J J, Morley, JS (1982) Selective antagonist at the opiate delta-receptor. Life Sci. 31: 1259–1261.CrossRefGoogle ScholarPubMed
Wand, P, Kuschinsky, K, Sontag, KH (1973) Morphine-induced muscular rigidity in rats. Eur. J. Pharmacol. 24: 189–193.CrossRefGoogle ScholarPubMed
Weiner, M (1982) Update on antiparkinsonian agents. Geriatrics 37: 81–91.Google ScholarPubMed
Wilcox, RE, Smith, RV, Anderson, JA, Riffee, WH (1980) Apomorphine-induced stereotypic cage climbing in mice as a model for studying changes in dopamine receptor sensitivity. Pharmacol. Biochem. Behav. 12: 29–33.CrossRefGoogle Scholar